64497-33-2

Basic information

• Product Name: 1-(2-Chlorophenyl)propane-1,2-dione
• Synonyms: 1-(2-Chlorophenyl)propane-1,2-dione
• CAS NO: 64497-33-2
• Molecular Formula: C₉H₇ClO₂
• Molecular Weight: 182.60368
• Mol File: 64497-33-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 276.4±23.0 °C(Predicted)
• Appearance: /
• Density: 1.246±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 1-(2-Chlorophenyl)propane-1,2-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-Chlorophenyl)propane-1,2-dione(64497-33-2)
• EPA Substance Registry System: 1-(2-Chlorophenyl)propane-1,2-dione(64497-33-2)

Safety Data

• Hazardous Substances Data: 64497-33-2(Hazardous Substances Data)

Usage

Description

1-(2-Chlorophenyl)propane-1,2-dione, commonly known as Clonazolam, is a designer drug that is part of the benzodiazepine class. It is characterized by its potent sedative and hypnotic properties, which are utilized in the treatment of anxiety, insomnia, and certain types of seizures. Clonazolam exerts its effects by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, thereby inducing a calming and relaxing response. However, due to its high potential for abuse and addiction, as well as the associated risks of harmful side effects, Clonazolam is subject to strict regulations and is not approved for medical use in the majority of countries.

Uses

Used in Pharmaceutical Industry:
1-(2-Chlorophenyl)propane-1,2-dione is used as a sedative and hypnotic medication for the treatment of anxiety disorders, insomnia, and specific seizure conditions. Its application is based on its ability to potently enhance GABAergic neurotransmission, which results in a calming effect on the body and brain.
Used in Neurological Treatments:
In the context of neurological treatments, 1-(2-Chlorophenyl)propane-1,2-dione serves as an adjunct therapy for certain types of seizures, where its strong sedative properties help in managing the symptoms and reducing the frequency of seizure episodes.

Upstream product

• 75-52-5 nitromethane 
• 2039-87-4 2-chlorostyrene 
• 77186-48-2 2-(2-chloro-phenyl)-acetoacetonitrile 
• 1346260-45-4 (E)-1-(2-chlorophenyl)-2-(methoxyimino)propan-1-one 
• 6305-95-9 2-chlorophenylacetone 
• 64543-64-2 1-(2-chloro-phenyl)-1-hydroxy-acetone 

Downstream Products

• 131504-95-5 3-bromo-1-(2-chlorophenyl)propane-1,2-dione 
• 1064136-45-3 1-((3-(2-chlorophenyl)-8-fluoroquinoxalin-2-yl)methyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1064136-57-7 1-((3-(2-chlorophenyl)-5-fluoroquinoxalin-2-yl)methyl)-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1065481-84-6 3-(bromomethyl)-2-(2-chlorophenyl)-5,6-difluoro-quinoxaline 
• 1065481-83-5 2-(bromomethyl)-3-(2-chlorophenyl)-5,6-difluoroquinoxaline 
• 1064137-32-1 3-(bromomethyl)-2-(2-chlorophenyl)-5-methylquinoxaline 
• 1064137-02-5 3-(bromomethyl)-2-(2-chlorophenyl)-5-fluoroquinoxaline 
• 1064137-43-4 3-(bromomethyl)-5-chloro-2-(2-chlorophenyl)quinoxaline 
• 1064137-46-7 2-(bromomethyl)-5-chloro-3-(2-chlorophenyl)quinoxaline 
• 1064137-04-7 2-(bromomethyl)-3-(2-chlorophenyl)-5-fluoroquinoxaline 

Relevant articles and documents

Palladium-catalyzed carbonation-diketonization of terminal aromatic alkenes via carbon-nitrogen bond cleavage for the synthesis of 1,2-diketones

A palladium-catalyzed carbonation-diketonization reaction of terminal alkenes via carbon-nitrogen bond cleavage under an atmosphere of oxygen has been developed. A series of 1,2-diketones were readily prepared from the reaction of aromatic terminal alkenes with nitroalkanes.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.